Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan

Yeu Jun Lau, Po Ren Hsueh, Yung Ching Liu, Jainn Ming Shyr, Wen Kuei Huang, Lee Jene Teng, Cheng Yi Liu, Kwen Tay Luh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We compared the in vitro activities of tigecycline to those of other agents against 300 nonduplicate isolates of Streptococcus pneumoniae (194 isolates), Haemophilus influenzae (60 isolates), and Moraxella catarrhalis (46 isolates) recovered from patients treated in three major hospitals in Taiwan from August through December, 2003. All of these isolates were inhibited at 0.5 mg/L of tigecycline. For S. pneumoniae isolates, 72% were not susceptible to penicillin (69% intermediate and 3% resistant) and 96% were not susceptible to azithromycin. Among the 178 isolates resistant to azithromycin, 53 isolates (30%) had the M phenotype and 70% had the cMLS B phenotype. The rate of nonsusceptibility to ertapenem, telithromycin, moxifloxacin, and quinupristin-dalfopristin in S. pneumoniae was 3%, 2%, 1%, and 57%, respectively. For H. influenzae, 36 (60%) were not susceptible to ampicillin, among which 31 possessed β-lactamase. A high rate (8.3%) of A influenzae isolates with β-lactamase-negative and ampicillin-resistant phenotype was found. All H. influenzae isolates were susceptible to azithromycin, but 40% of them were not susceptible to clarithromycin. Ninety-eight percent (44 isolates) of M. catarhalis possessed β-lactamase. All three fluoroquinolones tested were highly active (MIC 90

Original languageEnglish
Pages (from-to)130-135
Number of pages6
JournalMicrobial Drug Resistance
Volume12
Issue number2
DOIs
Publication statusPublished - Jun 2006
Externally publishedYes

Fingerprint

Moraxella (Branhamella) catarrhalis
Azithromycin
Haemophilus influenzae
Anti-Infective Agents
Streptococcus pneumoniae
Taiwan
Ampicillin
Phenotype
Clarithromycin
Fluoroquinolones
Penicillins
Human Influenza
tigecycline
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology
  • Immunology
  • Microbiology

Cite this

Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. / Lau, Yeu Jun; Hsueh, Po Ren; Liu, Yung Ching; Shyr, Jainn Ming; Huang, Wen Kuei; Teng, Lee Jene; Liu, Cheng Yi; Luh, Kwen Tay.

In: Microbial Drug Resistance, Vol. 12, No. 2, 06.2006, p. 130-135.

Research output: Contribution to journalArticle

Lau, Yeu Jun ; Hsueh, Po Ren ; Liu, Yung Ching ; Shyr, Jainn Ming ; Huang, Wen Kuei ; Teng, Lee Jene ; Liu, Cheng Yi ; Luh, Kwen Tay. / Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. In: Microbial Drug Resistance. 2006 ; Vol. 12, No. 2. pp. 130-135.
@article{fec74b1d2bcc48b0b5e67c075e91b5cc,
title = "Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan",
abstract = "We compared the in vitro activities of tigecycline to those of other agents against 300 nonduplicate isolates of Streptococcus pneumoniae (194 isolates), Haemophilus influenzae (60 isolates), and Moraxella catarrhalis (46 isolates) recovered from patients treated in three major hospitals in Taiwan from August through December, 2003. All of these isolates were inhibited at 0.5 mg/L of tigecycline. For S. pneumoniae isolates, 72{\%} were not susceptible to penicillin (69{\%} intermediate and 3{\%} resistant) and 96{\%} were not susceptible to azithromycin. Among the 178 isolates resistant to azithromycin, 53 isolates (30{\%}) had the M phenotype and 70{\%} had the cMLS B phenotype. The rate of nonsusceptibility to ertapenem, telithromycin, moxifloxacin, and quinupristin-dalfopristin in S. pneumoniae was 3{\%}, 2{\%}, 1{\%}, and 57{\%}, respectively. For H. influenzae, 36 (60{\%}) were not susceptible to ampicillin, among which 31 possessed β-lactamase. A high rate (8.3{\%}) of A influenzae isolates with β-lactamase-negative and ampicillin-resistant phenotype was found. All H. influenzae isolates were susceptible to azithromycin, but 40{\%} of them were not susceptible to clarithromycin. Ninety-eight percent (44 isolates) of M. catarhalis possessed β-lactamase. All three fluoroquinolones tested were highly active (MIC 90",
author = "Lau, {Yeu Jun} and Hsueh, {Po Ren} and Liu, {Yung Ching} and Shyr, {Jainn Ming} and Huang, {Wen Kuei} and Teng, {Lee Jene} and Liu, {Cheng Yi} and Luh, {Kwen Tay}",
year = "2006",
month = "6",
doi = "10.1038/sj.ijir.3901368",
language = "English",
volume = "12",
pages = "130--135",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan

AU - Lau, Yeu Jun

AU - Hsueh, Po Ren

AU - Liu, Yung Ching

AU - Shyr, Jainn Ming

AU - Huang, Wen Kuei

AU - Teng, Lee Jene

AU - Liu, Cheng Yi

AU - Luh, Kwen Tay

PY - 2006/6

Y1 - 2006/6

N2 - We compared the in vitro activities of tigecycline to those of other agents against 300 nonduplicate isolates of Streptococcus pneumoniae (194 isolates), Haemophilus influenzae (60 isolates), and Moraxella catarrhalis (46 isolates) recovered from patients treated in three major hospitals in Taiwan from August through December, 2003. All of these isolates were inhibited at 0.5 mg/L of tigecycline. For S. pneumoniae isolates, 72% were not susceptible to penicillin (69% intermediate and 3% resistant) and 96% were not susceptible to azithromycin. Among the 178 isolates resistant to azithromycin, 53 isolates (30%) had the M phenotype and 70% had the cMLS B phenotype. The rate of nonsusceptibility to ertapenem, telithromycin, moxifloxacin, and quinupristin-dalfopristin in S. pneumoniae was 3%, 2%, 1%, and 57%, respectively. For H. influenzae, 36 (60%) were not susceptible to ampicillin, among which 31 possessed β-lactamase. A high rate (8.3%) of A influenzae isolates with β-lactamase-negative and ampicillin-resistant phenotype was found. All H. influenzae isolates were susceptible to azithromycin, but 40% of them were not susceptible to clarithromycin. Ninety-eight percent (44 isolates) of M. catarhalis possessed β-lactamase. All three fluoroquinolones tested were highly active (MIC 90

AB - We compared the in vitro activities of tigecycline to those of other agents against 300 nonduplicate isolates of Streptococcus pneumoniae (194 isolates), Haemophilus influenzae (60 isolates), and Moraxella catarrhalis (46 isolates) recovered from patients treated in three major hospitals in Taiwan from August through December, 2003. All of these isolates were inhibited at 0.5 mg/L of tigecycline. For S. pneumoniae isolates, 72% were not susceptible to penicillin (69% intermediate and 3% resistant) and 96% were not susceptible to azithromycin. Among the 178 isolates resistant to azithromycin, 53 isolates (30%) had the M phenotype and 70% had the cMLS B phenotype. The rate of nonsusceptibility to ertapenem, telithromycin, moxifloxacin, and quinupristin-dalfopristin in S. pneumoniae was 3%, 2%, 1%, and 57%, respectively. For H. influenzae, 36 (60%) were not susceptible to ampicillin, among which 31 possessed β-lactamase. A high rate (8.3%) of A influenzae isolates with β-lactamase-negative and ampicillin-resistant phenotype was found. All H. influenzae isolates were susceptible to azithromycin, but 40% of them were not susceptible to clarithromycin. Ninety-eight percent (44 isolates) of M. catarhalis possessed β-lactamase. All three fluoroquinolones tested were highly active (MIC 90

UR - http://www.scopus.com/inward/record.url?scp=33746669944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746669944&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3901368

DO - 10.1038/sj.ijir.3901368

M3 - Article

C2 - 16922631

AN - SCOPUS:33746669944

VL - 12

SP - 130

EP - 135

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 2

ER -